1

張瑋婷(1)

Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia

SCI

2

張瑋婷(C)

施志遠(9)

陳志成(10)

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities

SCI

3

張瑋婷(4)

Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC)

SCI

4

張瑋婷(1)

施志遠(4)

陳志成(5)

Dynamic Changes in miR-21 Regulate Right Ventricular Dysfunction in Congenital Heart Disease-Related Pulmonary Arterial Hypertension

SCI

5

洪俊聲(1)

施志遠(6)

蔣俊彥(7)

陳志成(8)

張瑋婷(C)

Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study

SCI

6

張瑋婷(1)

黃柏森(3)

陳志成(7)

施志遠(8)

洪俊聲(9,C)

Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench

SCI

7

李威杰 (1)

The comparison of efficacy and safety between transradial and transfemoral approach for chronic total occlusions intervention: a meta-analysis.

SCI

8

張瑋婷(2)

High-Spatiotemporal-Resolution Visualization of Myocardial Strains Through Vector Doppler Estimation: A Small-Animal Study

SCI

9

李威杰(2)

Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock

SCI

10

李威杰 (1)

Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure.

SCI

11

張瑋婷(3,C)

Future perspectives of pulmonary hypertension treatment

SCI

12

施志遠(C)

張瑋婷(1)

陳志成(4)

洪俊聲(8)

Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT₃

SCI

13

郭芳秀(2)

廖家德(C)

Heart Failure and Polycythemia: A Case Report and Literature Review

SCI

14

張瑋婷(1)

施志遠(2)

陳志成(5)

miR-21 upregulation exacerbates pressure overload-induced cardiac hypertrophy in aged hearts

SCI

15

張瑋婷(12)

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

SCI

16

張瑋婷(3)

Evolutionary changes in thrombus features on computed tomography: An effective approach for identifying subacute pulmonary embolism

SCI

17

李威杰 (C)

Coronary Artery Bypass Graft Surgery Brings Better Benefits to Heart Failure Hospitalization for Patients with Severe Coronary Artery Disease and Reduced Ejection Fraction.

SCI

18

廖家德(2)

張瑋婷(5)

Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis

SCI

19

張瑋婷(1)

The Impact of Sildenafil on Ischemic Outcomes in Patients with Pulmonary Hypertension - A Nationwide Cohort Study

SCI

20

張瑋婷(1)

陳志成(4)

施志遠(5)

Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction

SCI

21

張瑋婷(1)

洪俊聲(2)

施志遠(6)

陳志成(8)

Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy

SCI

22

張瑋婷(1)

郭芳秀(3)

廖家德(4)

陳志成(6)

施志遠(C)

An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline

SCI

23

李威杰 (1)

Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients - A cohort study.

SCI

24

李威杰 (1)

The Relationship of Conduction Disorder and Prognosis in Patients with Acute Coronary Syndrome.

SCI

25

廖家德(4)

Lipoprotein profiles of fat distribution and its association with insulin sensitivity.

SCI

26

廖家德(C)

Quickly Convert Photoplethysmography to Electrocardiogram Signals by a Banded Kernel Ensemble Learning Method for Heart Diseases Detection

SCI

27

吳文憲(4)

Advanced glycation end products modulate electrophysiological remodeling of right ventricular outflow tract cardiomyocytes: A novel target for diabetes-related ventricular arrhythmogenesis

SCI

28

廖家德(10)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan

SCI

29

廖家德(6)

Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.

SCI

30

張瑋婷(5)

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan

SCI

31

林裕民(1)

張瑋婷(4)

陳嗣堯(5)

郭芳秀(6)

廖家德(C)

Association of sepsis-induced cardiomyopathy and mortality: a systematic review and meta-analysis.

SCI

32

廖家德(7)

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy

SCI

33

張瑋婷(5)

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan

SCI

34

郭芳秀(4)

張瑋婷(5)

林裕民(8)

陳嗣堯(9)

廖家德(C)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials

SCI

35

廖家德(C)

張瑋婷(6)

陳志成(7)

Economic evaluation of new blood pressure target for hypertensive patients in Taiwan according to the 2022 hypertension clinical practice guidelines of the Taiwan society of cardiology: a simulation modeling study

SCI

36

廖家德(6)

Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease

SCI